Daly James M 4
Research Summary
AI-generated summary
CYTOKINETICS (CYTK) Director James M. Daly Receives 191-Share Award
What Happened
- James M. Daly, a director of Cytokinetics, received 191 shares of common stock on 2026-04-15. The shares were registered at $65.37 each, for a total value of approximately $12,486. The transaction is reported as an acquisition/award (Code A) rather than an open-market purchase.
Key Details
- Transaction date and price: 2026-04-15; 191 shares @ $65.37 each.
- Total value: ~$12,486.
- Shares after transaction: not disclosed in the provided filing.
- Footnote: Shares granted pursuant to the Director Equity in Lieu of Cash Retainer Program and are fully vested (Footnote F1).
- Filing timeliness: Report filed on 2026-04-15 (same date as the transaction); no late filing indicated.
Context
- This was an award of shares (compensation) to a board director and not a sale or a market purchase. Because the shares are fully vested, they are not subject to future vesting conditions; such awards are commonly routine compensation for board service and do not by themselves indicate the insider’s short-term view on the stock.